compounded semaglutide or tirzepatide Program: Results, Timeline & Comparison WHY I DON'T PRESCRIBE COMPOUNDED

This could potentially affect the absorption of orally administered medications

HOW TO GET A GLP-1 RA One of the biggest challenges with GLP-1 RA is their cost and accessibility

Singhal V, Nimmala S, Karzar NH et al

But CMS announced in May 2026 that the Part D portion of the BALANCE Model will be delayed indefinitely and that the GLP-1 Bridge will be extended through December 31, 2027

Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability)